ENTX Entera Bio Ltd.

Entera Bio Ltd.

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

IPO Year: 2018

Exchange: NASDAQ

Website: enterabio.com

Peers

$BXRX

$PRVB

Recent Analyst Ratings for Entera Bio Ltd.

Date	Price Target	Rating	Analyst

See more ratings

Entera Bio Ltd.

Peers

Recent Analyst Ratings for Entera Bio Ltd.

Entera Bio Ltd. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Gautam Leslie Velka

Chief Operating Officer Galitzer Hillel was granted 26,316 units of Ordinary Shares, increasing direct ownership by 41% to 90,573 units (SEC Form 4)

Director Lieberman Gerald M exercised 23,952 units of Ordinary Shares at a strike of $1.00, increasing direct ownership by 9% to 300,160 units (SEC Form 4)

Director Taitel Haya was granted 6,922 units of Ordinary Shares, increasing direct ownership by 12% to 64,650 units (SEC Form 4)

Director Ostrov Gerald M was granted 8,038 units of Ordinary Shares, increasing direct ownership by 21% to 46,936 units (SEC Form 4)

Director Malca Yonatan was granted 8,216 units of Ordinary Shares, increasing direct ownership by 21% to 47,259 units (SEC Form 4)

Director Lieberman Gerald M was granted 10,717 units of Ordinary Shares, increasing direct ownership by 4% to 276,208 units (SEC Form 4)

Director Ellis Sean was granted 7,100 units of Ordinary Shares, increasing direct ownership by 6% to 134,727 units (SEC Form 4)

New insider Knoll Capital Management, Llc claimed ownership of 5,534,275 units of Ordinary Shares (SEC Form 3)

Director Taitel Haya was granted 7,278 units of Ordinary Shares, increasing direct ownership by 14% to 57,728 units (SEC Form 4)